( April 30, 2026, 2:32 PM EDT) -- WASHINGTON, D.C. — The U.S. Supreme Court heard oral argument April 29 on the standard for the inducement of infringement in medical patent cases, including ones that involve “skinny label” generic versions. A bioequivalent manufacturer told the high court that recent precedent emphasized that an entity must take active steps to induce infringement, while a patent-owning pharmaceutical company maintained that statements made by the bioequivalent maker did not clearly disclaim patented cardiovascular uses, thus inducing infringement....